ABSTRACT Background: Measurement errors in the dietary assessment of fruit and vegetable intake may attenuate associations with breast cancer risk and might explain the weak associations observed in epidemiologic studies. Carotenoid concentrations in blood are biomarkers of fruit and vegetable intake; however, no systematic assessment has compared dietary intake with blood concentrations of carotenoids and breast cancer risk. Objective: We conducted a systematic review and meta-analysis of prospective studies of dietary intake and blood concentrations of carotenoids and breast cancer risk. Design: We searched PubMed and several other databases for relevant studies up to 31 August 2011. Random-effects models were used to estimate summary estimates. 
INTRODUCTION
Intake of fruit and vegetables has been hypothesized to reduce the risk of breast cancer (1) . Several biologically plausible mechanisms could explain such a protective effect, including fiber, which can bind estrogens during the enterohepatic circulation, and antioxidants, which can prevent oxidative DNA damage (2) . However, prospective studies of dietary fruit and vegetable intakes and breast cancer risk have been inconsistent and have generally found weak and nonsignificant associations (3) (4) (5) (6) (7) . The evidence was considered too limited or inconsistent for a judgment in the World Cancer Research Fund/American Institute for Cancer Research report from 2007 (8) .
It is not clear whether the weak observed associations reflect true weak associations or attenuated risk estimates because of measurement errors in the assessment of dietary intake. Although the food-frequency questionnaire (FFQ) is a convenient and costeffective method for dietary assessment in large epidemiologic studies, increasing concern has been raised about measurement errors associated with the use of FFQs (9, 10) . The Observing Protein and Energy Nutrition Study used valid reference biomarkers of energy intake (doubly labeled water) and protein (urinary nitrogen) together with an FFQ and 24-h dietary recall and reported that a true relative risk of 2 would appear as 1.3 when FFQs are used to assess dietary intake (11) . Some studies have found stronger associations between diet and chronic disease risk when 1) correcting for measurement error by using calibration methods (12) (13) (14) (15) (16) (17) , 2) comparing dietary intake assessed by dietary records with data from FFQs (16, 18, 19) , or 3) comparing results from the use of biomarkers with results from the use of FFQs to assess exposure (20) (21) (22) (23) . This suggests that some diet-disease associations might have been underestimated because of measurement errors (24) .
Plasma carotenoids have been found to correlate with fruit and vegetable intakes in several cross-sectional (25) (26) (27) and intervention (28) (29) (30) studies, with correlations ranging from 0.1 to 0.7, and are considered to be biomarkers of fruit and vegetable intakes. All but one (31) of the prospective studies of dietary intake of carotenoids and breast cancer risk have shown no significant association (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) , similar to the results for fruit and vegetables (3, 8) . In contrast, several (42) (43) (44) (45) (46) (47) (48) (49) , but not all (50) (51) (52) (53) (54) , studies of plasma or serum concentrations of carotenoids and breast cancer reported stronger inverse associations, although they were not always statistically significant (44, (47) (48) (49) . To clarify these findings we conducted a systematic review and meta-analysis of prospective studies of dietary and blood concentrations of carotenoids and breast cancer risk.
METHODS

Search strategy
We updated the systematic literature review published in 2007 (8) as part of the Continuous Update Project and searched the PubMed database up to August 2011 for studies of blood concentrations, dietary intake, and supplemental intake of carotenoids and breast cancer risk. The literature search and data extraction up to December 2005 were conducted by several reviewers at Istituto Nazionale Tumori Milan. Initially, several databases were searched, including PubMed, Embase, CAB Abstracts, ISI Web of Science, BIOSIS, LILACS, Cochrane Library, CINAHL, AMED, National Research Register, and In Process Medline. Because all of the relevant prospective studies were identified by the PubMed searches, a change to the protocol was made and only PubMed was used for the updated searches. A prespecified protocol, which includes details of the search terms used, was followed for the review (http://www.dietandcancerreport. org/expert_report/scientific_process/slr.php). The reference lists of all of the studies that were included in the analysis were searched for further studies. Standard criteria for conducting and reporting meta-analyses were followed (55) .
Study selection
Prospective cohort, case-cohort, or nested case-control studies that investigated the association between dietary intake or blood concentrations of carotenoids and breast cancer incidence were included. Estimates of the RR (such as an HR, risk ratio, or OR) and 95% CIs had to be available in the publication. For the doseresponse analysis, a quantitative measure of the intake or blood concentration of carotenoids and the total number of cases and person-years or controls had to be available in the publication. When multiple publications from the same study were available, we used the publication with the largest number of cases or which reported the results in a manner that could be incorporated in meta-analysis. We identified 35 potentially eligible full-text publications (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) . We excluded 10 duplicate publications (51, (56) (57) (58) (59) (60) (63) (64) (65) (66) and 1 study of adolescent dietary intake (61) . In total, 24 publications were included in the analyses (Figure 1 ; see Supplementary Tables 1 and 2 under "Supplemental data" in the online issue) (31-50, 52-54, 62) .
Data extraction
We extracted the following data from each study: first author's last name, publication year, country where the study was conducted, study name, follow-up period, sample size, sex, age, number of cases, dietary assessment method (type, number of items, and validation status), laboratory method for analysis of blood carotenoids, exposure, exposure dose, RRs and 95% CIs, and variables adjusted for in the analysis. The data extraction of articles published up to 30 December 2005 was conducted by several reviewers at the Istituto Nazionale Tumori Milan and was checked for accuracy by DA. The data extraction from January 2006 up to August 2011 was conducted by DSMC and ARV and was checked for accuracy by DA and TN.
Statistical methods
To take into account heterogeneity between studies, we used a random-effects model to calculate summary RRs and 95% CIs for the highest compared with the lowest level of carotenoid exposure and for the dose-response analysis (67) . The average of the natural logarithm of the RRs was estimated, and the RR from each study was weighted by the inverse of its variance. A 2-tailed P value ,0.05 was considered statistically significant.
Details of the methods for the dose-response analysis have been published elsewhere (68) . Briefly, we used the method described by Greenland and Longnecker (69) to compute linear trends and 95% CIs from the natural logs of the RRs and CIs across categories of carotenoid exposure. We used mean or median values for the dose when provided in the articles but used the average of the upper and lower boundaries when the exposure was provided as a range. When extreme categories were openended or had extreme upper or lower values, we used the length of the adjacent interval to estimate the upper and lower boundaries for the category. For studies that reported plasma or serum concentrations of a-carotene, b-carotene, lycopene, and total carotenoids in mmol/L, we converted the data to mg/dL by dividing the concentration in mmol/L by 0.01863, whereas for studies of b-cryptoxanthin and lutein/zeaxanthin we divided the concentration in mmol/L by 0.01809 and 0.01758, respectively (70) . For the linear dose-response analysis we used an increment with the size of the approximate mean difference between the highest and lowest exposure across studies. A potential nonlinear dose-response relation between carotenoid exposures and breast cancer was examined by using fractional polynomial models (71) . We determined the best-fitting second-order fractional polynomial regression model, defined as the one with the lowest deviance. A likelihood ratio test was used to assess the difference between the nonlinear and linear models to test for nonlinearity (72) . Heterogeneity between studies was assessed by using Q and I 2 statistics (73). We did not assess study quality by using a quality score but investigated whether specific study characteristics such as duration of follow-up, number of cases, menopausal status, and adjustment for confounders, which are indicators of study quality, influenced the results or explained potential heterogeneity in subgroup analyses. Subgroup analyses were conducted for exposures with $6 studies in the analysis.
Small-study effects, such as publication bias, were assessed by using a funnel plot and Egger's test (74) , and the results were considered to indicate potential small-study bias when P values were ,0.10. Stata version 10.1 software (StataCorp) was used for the statistical analyses.
RESULTS
A total of 24 publications from 25 prospective studies were included in the analyses (31-50, 52-54, 62) . Twelve cohort studies were included in the analyses of dietary carotenoid intakes and breast cancer risk (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) 53) , and 2 cohort studies were included in the analysis of supplemental b-carotene and breast cancer risk (Table 1 ) (31, 62) . Fourteen nested casecontrol studies (11 publications) (42-46, 48-50, 52-54) and a follow-up study of participants in a clinical trial (47) were included in the analyses of blood concentrations of carotenoids and breast cancer risk ( Table 2) . One publication reported results from 2 separate nested case-control studies (45) . Another publication reported results from 3 nested case-control studies, 2 of which were pooled (The Västerbotten Intervention Project and Monitoring of Trends in Cardiovascular Disease) (44) . Fourteen studies of dietary carotenoid intake and blood concentrations of carotenoids and breast cancer risk were from the United States, 10 were from Europe, but only 1 study was from Asia (Tables 1 and 2 ).
Total dietary carotenoid intake
Three prospective studies were included in the analysis of total dietary carotenoids and breast cancer risk (34, 36, 39) . No association was found between total dietary carotenoid intake and breast cancer (see Supplementary Figure 1A under "Supplemental data" in the online issue; Figure 2A) . No evidence of small study effects was observed (P = 0.74), although the number of studies was small, and no evidence of a nonlinear association between total carotenoid intake and breast cancer risk was observed (P-nonlinearity = 0.14; Figure 2B ).
Dietary and supplemental b-carotene
Ten prospective studies were included in the analysis of dietary b-carotene intake and breast cancer risk (31) (32) (33) (35) (36) (37) (38) (39) (40) (41) and included 18,191 cases among 775,765 participants. The summary RR for high compared with low intake was 0.93 (95% CI: 0.88, 0.98; I 2 : 0%, P-heterogeneity = 0.76) (see Supplementary  Figure 2A under "Supplemental data" in the online issue). The summary RR for a 5000-mg/d increment in b-carotene intake was 0.95 (95% CI: 0.91, 0.99) ( Figure 3A) . No evidence of small study effects (P = 0.63) or of a nonlinear association between b-carotene intake and breast cancer risk (P-nonlinearity = 0.33) was observed ( Figure 3B ).
Two cohort studies including 3951 cases among 111,029 participants reported results for supplemental b-carotene intake and breast cancer risk (31, 62) . No significant association was found between supplemental b-carotene and breast cancer risk (see Supplementary Figure 3A and 3B under "Supplemental data" in the online issue).
Dietary a-carotene
Six prospective studies were included in the analysis of dietary a-carotene intake and breast cancer risk (31, (36) (37) (38) (39) 41) and included 9461 cases among 413,575 participants. No significant association was found between dietary a-carotene intake and breast cancer risk (see Supplementary Figure 4A under "Supplemental data" in the online issue; Figure 4A ). No evidence of small study effects was observed (P = 0.18). There was evidence of a nonlinear association between a-carotene intake and breast cancer risk (P-nonlinearity , 0.0001). A weak risk reduction at intakes of w1500 mg/d (summary RR: 0.91; 95% CI: 0.85, 0.97) was suggested, but no further reduction was suggested with higher intakes ( Figure 4B ).
Dietary b-cryptoxanthin
Six prospective studies were included in the analysis of dietary b-cryptoxanthin and breast cancer risk and included 9461 cases among 413,575 participants (31, (36) (37) (38) (39) 41) . No association between dietary b-cryptoxanthin intake and breast cancer risk was observed (see Supplementary Figures 5A and 6A under "Supplemental data" in the online issue). No evidence of small study effects (P = 0.67) or of a nonlinear association (P-nonlinearity = 0.27) was found between dietary b-cryptoxanthin and breast cancer risk (see Supplementary Figure 6B under "Supplemental data" in the online issue).
Dietary lycopene
Seven studies were included in the analysis of dietary lycopene intake and breast cancer risk and included 10,537 cases among 452,022 participants (31, 36-39, 41, 53) . No association between dietary lycopene intake and breast cancer risk was found (see Supplementary Figures 7A and 8A under "Supplemental data" in the online issue), and no evidence of small study effects was found (P = 0.73). Although the test for nonlinearity was significant (P-nonlinearity , 0.0001), with a suggestion of a weak positive association with very high intakes, this may have been driven by one large study with higher intakes (37) (see Supplementary Figure 8B under "Supplemental data" in the online issue).
Dietary lutein/zeaxanthin
Five studies were included in the analysis of dietary lutein/ zeaxanthin and breast cancer risk and included 8750 cases among 302,049 participants (31, 36, 37, 39, 41) . No association between dietary lutein/zeaxanthin and breast cancer risk was found (see Supplementary Figures 9A and 10A under "Supplemental data" in the online issue). No evidence of small study effects was found (P = 0.85). Although the test for nonlinearity was significant (P-nonlinearity , 0.0001), there may have been a cohort effect with results driven by one large study with higher intakes (36) (see Supplementary Figure 10B under "Supplemental data" in the online issue).
Total carotenoids in blood
Seven studies (6 publications) were included in the analysis of blood concentrations of total carotenoids and breast cancer risk (43, 45, 46, 48, 49, 54) , including 2518 cases among 6003 participants. The summary RR for high compared with low blood concentrations of carotenoids was 0.74 (95% CI: 0.57, 0.96) with moderate heterogeneity (I 2 : 52%; P-heterogeneity = 0.05; see Supplementary Figure 1B under "Supplemental data" in the online issue). The summary RR for a 100-mg/dL increase in blood concentrations of total carotenoids was 0.78 (95% CI: 0.61, 0.99) with moderate heterogeneity (I 2 : 53%; P-heterogeneity = 0.05; Figure 2C ). Exclusion of the only Asian study (the Shanghai Women's Health Study) (54) from the analysis reduced the FIGURE 2. Dietary and blood concentrations of total carotenoids and breast cancer risk (dose-response analysis). Summary estimates were calculated by using a random-effects model. heterogeneity, but the results remained similar (summary RR: 0.73; 95% CI: 0.61, 0.87; I 2 : 6%; P-heterogeneity = 0.38). No evidence of small study effects (P = 0.43) or of a nonlinear association (P-nonlinearity = 0.45) was found ( Figure 2D ).
b-Carotene in blood
Fifteen studies (12 publications, 14 risk estimates) were included in the analysis of blood concentrations of b-carotene and breast cancer risk (42-50, 52-54), including 3609 cases among 13,511 participants. One of these studies was excluded from the dose-response because the exposure was provided in only 2 categories (50). The summary RR for high compared with low exposure was 0.82 (95% CI: 0.65, 1.04) with moderate heterogeneity (I 2 : 55%; P-heterogeneity = 0.007; see Supplementary Figure 2B under "Supplemental data" in the online issue). The summary RR for a 50-mg/dL increase in blood concentrations of b-carotene was 0.74 (95% CI: 0.57, 0.97) ( Figure 3C ). Exclusion of the Shanghai Women's Health Study (54) also reduced the heterogeneity in this analysis but did not substantially alter the summary estimate (summary RR: 0.71; 95% CI: 0.55, 0.90; I 2 : 35%; P-heterogeneity = 0.12). No evidence of small study effects was found (P = 0.69). The test for nonlinearity was not significant (P-nonlinearity = 0.14; Figure 3D ).
a-Carotene in blood
Thirteen studies (10 publications, 12 risk estimates) were included in the analysis of blood concentrations of a-carotene in blood and breast cancer risk (43-49, 52-54), including 3531 cases among 13,277 participants. The summary RR for high compared with low exposure was 0.80 (95% CI: 0.68, 0.95) with low heterogeneity (I 2 : 15%; P-heterogeneity = 0.30; see Supplementary Figure 4B under "Supplemental data" in the online issue). The summary RR for a 10-mg/dL increase in blood concentrations of a-carotene was 0.82 (95% CI: 0.73, 0.92) ( Figure 4C ). No evidence of small study effects (P = 0.60) or of a nonlinear association (P-nonlinearity = 0.25) was found ( Figure 4D ).
b-Cryptoxanthin in blood
Eleven studies (8 publications, 10 risk estimates) were included in the analysis of blood concentrations of b-cryptoxanthin and breast cancer risk including 2861 cases among 11,385 participants (43-47, 49, 52, 53) . No significant association was found between blood concentrations of b-cryptoxanthin and breast cancer risk (see Supplementary Figures 5B and 6C under "Supplemental data" in the online issue). No evidence of small study effects (P = 0.63). No evidence of a nonlinear association (P-nonlinearity = 1.00) was found (see Supplementary Figure 6D under "Supplemental data" in the online issue).
Lycopene in blood
Thirteen studies (10 publications, 12 risk estimates) were included in the analysis of blood concentrations of lycopene and breast cancer risk, including 3512 cases and 13,297 participants (43) (44) (45) (46) (47) (48) (49) (52) (53) (54) . No association was found between blood concentrations of lycopene and breast cancer risk (see Supplementary  Figures 7B and 8C under "Supplemental data" in the online issue). No evidence of small study effects (P = 0.23) or of a nonlinear association (P-nonlinearity = 0.71) was found (see Supplementary Figure 8D under "Supplemental data" in the online issue).
Lutein/zeaxanthin in blood
Four studies were included in the analysis of blood concentrations of lutein/zeaxanthin and breast cancer risk, including 1675 cases among 8521 participants (46, 47, 52, 53) . No association was observed between lutein/zeaxanthin in blood and breast cancer risk (see Supplementary Figures 9B and 10C under "Supplemental data" in the online issue). No evidence of small study effects (P = 0.32) or of a nonlinear association (P-nonlinearity = 0.31) was found (see Supplementary Figure 10D under "Supplemental data" in the online issue).
Lutein in blood
Seven studies (4 publications, 6 risk estimates) were included in the analysis of lutein in blood and breast cancer risk and included 1186 cases among 2864 participants (43) (44) (45) 49) . The summary RR for high compared with low exposure was 0.70 (95% CI: 0.52, 0.96; I 2 : 21%; P-heterogeneity = 0.28; see Supplementary Figure  11A under "Supplemental data" in the online issue). The summary RR for a 25-mg/dL increase in blood concentrations of lutein was 0.68 (95% CI: 0.52, 0.89) ( Figure 5A ). No evidence of small study effects (P = 0.67) or of a nonlinear association (P-nonlinearity = 0.32) was found ( Figure 5B ).
Zeaxanthin in blood
Five studies (3 publications, 4 risk estimates) were included in the analysis of blood concentrations of zeaxanthin and breast cancer risk and included 827 cases among 2146 participants (43, 44, 49) . No association between zeaxanthin in blood and breast cancer risk was found (see Supplementary Figures 11B and 12A under "Supplemental data" in the online issue). No evidence of small study effects (P = 0.40) or of a nonlinear association (P-nonlinearity = 0.36) was found (see Supplementary Figure 12B under "Supplemental data" in the online issue).
Subgroup and sensitivity analyses
In stratified analyses, there was no evidence of heterogeneity between subgroups of studies that investigated dietary b-carotene, a-carotene, b-cryptoxanthin, or lycopene and breast cancer risk (see Supplementary Tables 1 and 2 under "Supplemental data" in the online issue). The association between increased blood concentrations of carotenoids and breast cancer risk was inverse in several, but not in all, strata (see Supplementary Tables 3 and 4 under "Supplemental data" in the online issue), although not always statistically significant. There was some suggestion that duration of follow-up explained part of the heterogeneity for total carotenoids and b-carotene in blood (P-heterogeneity = 0.09 and 0.04, respectively). A stronger association was found among studies with $10 y of follow-up than among studies with ,10 y of follow-up. In addition, evidence of heterogeneity was found between studies that adjusted for smoking or not in the analysis of blood concentrations of b-carotene (P-heterogeneity = 0.01) and borderline evidence of heterogeneity between studies that adjusted for BMI, physical activity, or energy intake (for b-carotene and total carotenoids); no association was found in studies with such adjustments, although the number of studies in some of these subgroups was small (see Supplementary Table 3 under "Supplemental data" in the online issue). No significant heterogeneity was found between subgroups in the analyses of blood concentrations of a-carotene, b-cryptoxanthin, lycopene, and lutein and breast cancer risk (see Supplementary Tables 3 and 4 under "Supplemental data" in the online issue).
When we restricted the analysis to the 2 studies that had published on both dietary and blood concentrations of b-carotene and a-carotene (31, 36, 46, 47) , the summary RR was 0.90 (95% CI: 0.84, 0.98) for dietary b-carotene and 0.71 (95% CI: 0.55, 
DISCUSSION
In this meta-analysis, no association was found between dietary intake of carotenoids and breast cancer risk, except for a weak reduction in risk with dietary b-carotene. However, blood concentrations of total carotenoids, b-carotene, a-carotene, and lutein were more strongly associated with reductions in breast cancer risk.
Our results may have some limitations that deserve comment. Although significant heterogeneity in the analyses of blood concentrations of total carotenoids and b-carotene was observed, the heterogeneity was explained by one study conducted in China (54) . The reason for these inconsistent results is not clear, but genetic factors or chance could be involved. It is also possible that the sources of carotenoids in this population differ from those in Western populations. In addition, there was some suggestion that duration of follow-up explained part of the heterogeneity among studies of blood concentrations of total carotenoids and b-carotene, with a stronger association among studies with $10 y of follow-up, although these results were based on only 2 and 4 studies, respectively. However, this finding may have been a result of chance or other unidentified study characteristics, because one would expect that changes in carotenoid concentrations during follow-up would weaken risk estimates when only baseline blood measurements are used, because of regression dilution bias, unless distant exposure is more relevant. There was moderate to high heterogeneity in the analyses of total dietary carotenoids and a-carotene, but not for the other carotenoids; however, we found no explanation for this heterogeneity.
We cannot exclude the possibility that the observed inverse association between dietary b-carotene intake or blood concentrations of carotenoids and breast cancer risk could be a result of unmeasured or residual confounding. Persons with higher carotenoid exposures may have higher levels of physical activity, lower prevalences of overweight/obesity, and lower intakes of alcohol and dietary fat. Many but not all of the studies included in this meta-analysis adjusted for these and other potential confounders. In subgroup and meta-regression analyses, no evidence of between-subgroup heterogeneity in the dietary analyses was found, but there was no association in the subgroup analyses of blood concentrations of carotenoids that were adjusted for BMI, physical activity, and energy intake, although the number of studies was small in some of these analyses. Any further studies might want to assess whether adjustment for more confounders has any influence on the risk estimates.
Carotenoids are found in various fruit and vegetables, and epidemiologic studies found that intake of carrots, broccoli, and green and raw vegetables correlated most with blood concentrations of a-carotene, b-carotene, and lutein/zeaxanthin (26, 49) , whereas citrus fruit was additionally correlated with blood concentrations of lutein (26, 49) . Although intake of fruit and vegetables has been hypothesized to reduce breast cancer risk, epidemiologic studies have mostly shown weak associations. A pooled analysis of 7 prospective studies found a nonsignificant 6-7% reduction in the relative risk of breast cancer with a high intake of fruit and fruit and vegetables combined, but no association with intake of vegetables (3), and more recently a pooled analysis of 18 cohort studies found no association between intakes of most carotenoids and breast cancer risk and only a 5% reduction in the RR with intake of b-cryptoxanthin (75). Our results for dietary carotenoids are similar to these results. However, when blood measures of carotenoids were analyzed, we found significant inverse associations for total carotenoids, b-carotene, a-carotene, and lutein. Women with the highest blood concentrations of carotenoids had a 20-30% reduction in risk of breast cancer compared with those with the lowest concentrations, considerably stronger than the results from the analysis when carotenoid exposure was measured by dietary questionnaires. When we restricted the analysis to the only 2 studies that reported results for both dietary and blood carotenoids, we also found a stronger inverse association with blood measures of carotenoids than with dietary intake. Thus, it is possible that measurement errors in the dietary assessment may have obscured an association between intake of carotenoids and breast cancer risk. Likewise, it is possible that the association between fruit and vegetable intake as assessed by dietary questionnaires and breast cancer risk may have been underestimated.
The interpretation of our results was also complicated because dietary assessment of carotenoid intake may not reflect bioavailability as their absorption may be influenced by several factors including degree of processing or cooking of foods, the lipid content of the diet, degree of fermentation in the colon, menstrual cycle and hormonal factors, and possibly genetic factors (76) . In addition, the metabolism of carotenoids can affect their blood concentrations and reduce their correlation with dietary intake. Carotenoids can be metabolized to retinol, particularly in subjects with low vitamin A status; in addition, smoking and high alcohol consumption may reduce blood concentrations of carotenoids (76) .
Our meta-analysis also had several strengths. Because we based our analyses on prospective studies, we minimized the possibility that our findings may have been because of recall bias. The studies included a large number of cases and participants, which provided sufficient statistical power to detect moderate reductions in risk. However, our findings indicate the importance of improving exposure measurement and increasing the sample size to detect associations between dietary-related exposures and disease risk.
Several mechanisms could explain a protective effect of carotenoids on breast cancer risk. Carotenoids may act as antioxidants by quenching free radicals and protecting against DNA damage (2) . b-Carotene may reduce cell proliferation and induce apoptosis (77, 78) and may interfere with estrogen signaling in breast cancer cells (77, 79) . However, the inverse associations between blood concentrations of carotenoids and breast cancer risk we observed may not be solely a result of the effect of single antioxidants. Blood concentrations of carotenoids are biomarkers of intake of fruit and vegetables, which contain a myriad of bioactive compounds, including fiber, flavonoids, and other antioxidants, that may act synergistically to reduce breast cancer risk (2, 80, 81) .
In conclusion, we found a significant inverse association between blood concentrations of total carotenoids, b-carotene, a-carotene, and lutein and breast cancer risk. In contrast, only a very weak inverse association with the dietary intake of b-carotene was found, and no association between the other dietary carotenoids and breast cancer risk was found. Our results suggest that the use of certain biomarkers may clarify inconsistent and weak results between dietary intake and breast cancer risk. Additional prospective studies with adjustment for more confounding factors are warranted.
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